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a metastatic lesion.[2–9] The detection of 
CTCs in patient blood is associated with 
reduced overall survival (OS) in various 
cancer types.[10–12]
Currently, cancer is primarily diag-
nosed by tissue biopsy, an invasive proce-
dure that can lead to side effects such as 
bleeding and infection and is not feasible 
in all tissues (e.g., brain). Additionally, 
information gained by biopsy is limited to 
the site of tissue removal and furthermore 
cannot mirror the ever changing land-
scape of tumor evolution within a single 
patient. Blood-based analysis of CTCs 
could therefore function as a minimal 
invasive “liquid biopsy,” allowing repeated 
sampling, a more holistic overview on dis-
ease development, and additional insights into the biology of 
metastasis formation.[13,14]
When analyzing CTCs, the main hurdle is the rarity of these 
cells in the background of millions of blood cells (≈1 CTC in 
108 blood cells).[15] To overcome this limitation, a multitude of 
assays have been and are currently under development.[3,16] 
However, so far only the CellSearch system (Menarini Silicon 
Biosystems, Italy) has gained approval for use in specific cancer 
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Cancer remains the second most common cause of death 
worldwide.[1] As 90% of cancer-related deaths are caused by 
the formation of distant metastasis, understanding and pre-
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entities by the American Food and Drug Administration (FDA). 
While this system has been extensively validated, its limitation lies 
in the dependence of its CTC capture on EpCAM epithelial cell 
adhesion molecule (EpCAM).[17] While EpCAM is expressed on 
most epithelial tissues and therefore carcinoma cells, a growing 
amount of evidence is indicating that tumor cells undergo transi-
tion to a more mesenchymal state when initiating the metastatic 
cascade.[18,19] These cells downregulate epithelial markers such as 
EpCAM and therefore would most likely not be detected by the 
CellSearch system. This necessitates the development of prom-
ising and highly sensitive EpCAM-independent CTC detection 
platforms in order to isolate these highly aggressive CTC subtypes.
Recently, we developed a different approach in microfluidic 
CTC capture, based on a microfluidic encapsulated micro-
array.[20] Here, the CTC-containing samples are incubated with 
an antibody targeting the desired surface marker and then intro-
duced into a microfluidic chip with a herringbone structured 
ceiling (Figure 1). The ceiling structure disrupts laminar stream-
lines and, thereby, enhances the number of cellular interactions 
with the reactive micropattern, comprising the specific binding 
sites for the CTCs. Thus, CTCs are immobilized on the array, 
while healthy cells leave the microfluidic chip on the outlet. 
The microarray within the microfluidic channel was printed 
via polymer pen lithography (PPL).[21] This technique combines 
aspects of microcontact printing and dip-pen nanolithography 
(DPN)[22] in a hybrid way and allows large area (several cm²) pat-
terning,[23] especially for sensitive, bioactive molecules in gra-
dients[24,25] and in a multiplexed fashion.[26–29] This allows also 
easy integration into microfluidic systems as we demonstrated 
for the above-mentioned application of CTC capture[20] and mast 
cell screening,[30] recently. In the application of these micro-
arrays for CTC capture, the design of the microfluidic chip 
chamber ceiling is key to disrupt laminar streamlines in order 
to get CTCs into contact with the specific binding sites on the 
microarray. Structuring the channel ceiling with a staggered her-
ringbone (SHB) design has proven to be an effective method to 
increase the number of cell–surface contacts. Originally, SHBs 
were proposed as a chaotic mixer for micro channels by Strook 
et al.[31] They showed that SHB mixers generate transverse flows 
that induce a stirring within the microchannel. These micro-
vortices lead to stretching and folding of fluid volumes over the 
channel’s cross section. Thereby, the diffusion length is reduced 
and, hence, mixing is significantly accelerated.
Stott et al. were among the first to apply the SHB mixer 
design to the isolation of CTCs.[32] Since then, SHBs have been 
utilized frequently for CTC capture.
The initial SHB design has been proposed and optimized for 
mixing purposes. For the purpose of capturing CTCs the aim is 
not mixing but transporting cells to a binding surface. On that 
account, Forbes et al. developed a computational model and a 
theoretical framework to optimize the geometry of the SHB 
design.[33] Recently, Lynn et al. have optimized the design of the 
SHB mixer for biosensing purposes as well, focusing on analyte 
transfer to the surface opposite the SHB grooves.[34,35] Consid-
ering the importance and benefits of theoretical and simulation 
results in the design process of microfluidics,[36] we set out to 
implement and compare these propositions in practice.
In the present work, we evaluate our chip platform with dif-
ferent SHB structures as suggested in the literature. As dif-
ferent herringbone structures are theoretically proposed for 
maximum efficiency of analyte delivery to active channel sur-
face, we compare three different setups: design HA is the SHB 
design that we utilized in a previous publication,[20] design HB 
implements the suggestions of Forbes et al.,[33] and design HC 
follows the design rules that Lynn et al.[34,35] proposed. Addi-
tionally, the capture efficiency of a channel with smooth walls is 
included in the comparison.
2. Results and Discussions
2.1. The Chip Platform
In order to assess the influence of the different SHB structures 
in the chip ceiling (Figure 2) on the capture efficiency of the 
chip platform, three different designs were produced (Table 1, 
called ceiling type HA, HB, HC) and compared with each 
other as well as an unstructured microfluidic channel. The her-
ringbone is composed of a series of chevrons with a long and 
a short groove. The short groove covers one third of the sym-
metry width whb and the long groove covers the remaining two 
thirds. The angle between grooves θhb is 90° and the angle with 
the channel wall θc is 45°.
Each chevron is whb wide and placed side by side to cover the 
complete channel width wc. Grooves are wg wide, hg high and 
separated with a pitch Λ. The height of the smooth part of the 
channel is hc. The shape of the SHBs is varied as a function of 
the axial position in the microchannel. After Ng chevrons per 
part-cycle, they are staggered by an offset δg.
Publications by Forbes et al. and Lynn et al. on geometrical opti-
mization of the SHB design provide design guidelines to enhance 
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Figure 1. The CTC capture chip. a) Scheme of the capture principle. 
Antibody sensitized CTCs are captured on a microarray at the channel 
bottom, while other cells can pass the microfluidic chip. Structures in the 
channel ceiling ensure frequent contacts of cells with the microarray by 
inducing transverse flows. b) Photograph of a real microfluidic chip on 
an inverted microscope.
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the number of particle–surface interactions in SHBs.[33–35] How-
ever, the results published by these two groups contradict each 
other in the following parameters: groove width wg, groove height 
hg, and symmetry width whb. Nevertheless, they agree that the 
groove pitch Λ has little or no effect on capture efficiency.
Forbes et al. focus on the groove-to-channel relative hydraulic 
resistance and suggest that SHBs with wide and deep grooves 
enhance the number of interactions at the surface opposite to 
the SHBs.[33] Consequently, the geometrical parameters, labeled 
HB in Table 1, were chosen.
Lynn et al. conclude that the ratio hg/hc is one of the most 
important design parameters and should be in the region of 
1.2 < hg/hc.[34,35] As the channel height is 50 µm, the groove 
height was chosen to be 75 µm, resulting in hg/hc = 1.5. The 
geometrical parameters following these suggestions are given 
in Table 1, labeled HC.
To find the optimal SHB structure for CTCs capture pur-
poses, the designs HB and HC were fabricated and their cap-
ture efficiency was evaluated experimentally. Additionally, 
the SHB design that was utilized in a previous publication 
by our group, labeled HA, and a smooth channel with height 
hc = 150 µm were included in the comparison.
All designs have the following parameters in common: com-
plete channel width wc  = 9600 µm, number of grooves per part-
cycle Ng = 5, angle of herringbone θhb  = 90° and the angle with 
channel wall θc = 45°.
2.2. Performance in Tumor Cell Capture
To compare the performance of the different ceiling types for 
the microarray chip platform, trials with different concentra-
tions of cancer cell line cells were performed. Mixtures of 100 
and 10 000 biotinylated cancer cells (MCF-7) and 104 to 106 non-
biotinylated cancer cells were tested on the different microflu-
idic chips (different pattern pitches and chamber designs). A 
streptavidin-patterned chip surface with an array feature pitch 
of 50 µm combined with the SHB design type HC showed the 
highest capture rate among the different tested combinations 
(Figure 3c and Table S1, Supporting Information).
Statistical analyses showed that both the ceiling type 
(p = 0.0015) and pattern structure (p < 0.0001) had a significant 
impact on the capture rate, with a possible interaction between 
the two (p = 0.0089), cell suspension concentration was also 
significantly correlated to the capturing rate (p = 0.044), but 
not as strong and was therefore not further considered. Pair-
wise analyses indicated that ceiling type HB was outperformed 
by HA with 29.8% (95% CI: [10.1, 49.4], p = 0.0019) and HC 
with 30.8% (95% CI: [9.2, 52.3], p = 0.0034), whereas the 
smooth ceiling type was not highly statistically different com-
pared to the other three (p > 0.005). The pattern structure of 
50 µm showed a 25.2% better mean capturing than the 25 µm 
(95% CI: [11.0, 39.5], p = 0.0006) and a 28% better capturing 
than the homogeneous pattern structure (95% CI: [13.1, 42.9], 
p = 0.0003). Interaction effects between the ceiling type and 
pattern structure confirmed that 60% higher mean recovery 
rates could be achieved with the 50 µm herringbone HA and 
HC compared to the smooth type or HB (p < 0.005). No sta-
tistically significant difference in the mean rate of capture was 
detected between ceiling types HA and HC at the same pattern 
structure.
Based on these results, a pattern pitch of 50 µm was chosen 
(as here the overall highest recovery performance was found) 
for subsequent experiments to allow more in-depth comparison 
across the different chip designs under “mock” blood sample 
conditions. Here, 100 cancer cell line cells (MCF-7) were spiked 
into blood samples of healthy donors (containing around 5 × 
109 cells mL−1). As described previously,[20] these “mock” blood 
samples were subjected to a size-based pre-enrichment by the 
Parsortix system. This workflow allows for removal of a large 
fraction of healthy white blood cells and erythrocyte background 
by size exclusion.[37] After pre-enrichment, the remaining cells 
(1500–6000 dependent on donor)[38,39] were sensitized by bioti-
nylated-anti-EpCAM antibodies and pumped into the respective 
chip. Following additional staining with fluorescently labeled 
antibodies (secondary anti-mouse, DAPI, CD45), the tumor 
cells bound on the chip surface were manually counted with an 
upright fluorescence microscope.
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Figure 2. Scheme of chip ceilings. Schematic of a staggered herringbone 
design, illustrating the geometrical parameters: channel height hc, groove 
height hg, groove width wg, groove pitch Λ, symmetry width wHR, number 
of chevrons per part-cycle Ng and offset per cycle δg.
Table 1. Design parameters of the staggered herringbone ceiling.
Geometrical parameter HA [µm]a) HB [µm]b) HC [µm]c)
Channel height hc 50 50 50
Groove height hg 50 150 75
Groove width wg 100 125 50
Groove pitch Λ 100 200 100
Symmetry width whb 300 500 150
Offset per cycle δg 100 500 150
a)As used in our previous publication[20]; b)Following design rules by Forbes 
et al.[33]; c)Following design rules by Lynn et al.[34,35]
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Representative images of stained tumor cells captured on 
the streptavidin dots of the chip are shown in Figure 3a,b. As 
median recovery for the different ceiling types, 10% for smooth, 
13% for type HA, 3% for type HB, and 38% for type HC, respec-
tively, were obtained (Figure 4). The standard deviations (SD) 
measured here represent an accumulation of the SD of both the 
pre-enrichment via Parsortix, and the actual chip processing. 
The SD of the HC chip appears to be higher than in the other 
chips which is most likely due to the fact that more cells can be 
detected with this compared to the other chip types (e.g., HB). 
It is natural for the variation in recovery to decrease the closer 
the recovery is to zero. Since the recovery obtained with the HC 
chip among the different experiments is normally distributed, 
the results remain highly trustworthy. Nonetheless, we will 
strive to further improve the reproducibility in future experi-
ments. Statistical analysis shows a significant difference in 
the mean recovery rate between the ceiling types (p = 0.0006). 
Type HC outperformed the smooth type with 30.3% (95% CI: 
[11.8, 48.7], p = 0.0025), type HA with 22.9% (95% CI: [4.5, 
41.4], p = 0.015), and type HB with 34.6% (95% CI: [16.1, 53.1], 
p = 0.0009). No statistically significant difference was detected 
between type HA and HB (p = 0.35), HA and smooth (p = 0.70), 
and HB and smooth (p = 0.92). Taken together, the HC type 
(designed as suggested by the Lynn et al. rules for maximiza-
tion of the number of surface interactions)[34,35] shows the 
overall best recovery performance and significantly improves 
on our previously used[20] HA type and the HB type (based 
on the alternative design rules suggested by Forbes et al.).[33] 
Current standard approaches used downstream of the Par-
sortix system, such as the classical ICC staining on cytospins 
(pan-cytokeratin, CD45, and DAPI) reach an average recovery of 
(32 ± 4)% using MCF-7 cells and the same Parsortix separation 
protocol (Table S2, Supporting Information). Of note, a broader 
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Figure 3. Captured cells on a microarray and correlation matrix of examined chip and pattern designs. a) Single captured CTC on a microarray. The 
translucent herringbone ceiling structure is visible. Scale bar equals 250 µm. b) Close-up of the cell. Note the low background of other cells and the 
co-localization of microarray pattern with the captured CTC. Scale bar equals 50 µm. c) Correlation matrix showing the recovery of tumor cells under 
the different experimental conditions of the ceiling type (Herringbone, top row), pattern design (Pattern, center row), and the cell suspension concen-
tration (Suspension, bottom row).
Figure 4. Capture efficiency in spiked blood samples. Ceiling type HC 
(median recovery 38%) outperforms the other ceiling types significantly. 
No statistically significant differences were detected between the smooth 
ceiling (median recovery 10%) and ceiling types HA (median recovery 
13%) and HB (median recovery 3%).
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discussion and comparison of different CTC isolation systems 
can be found in the literature.[3,40,41] Factoring in these losses in 
the upstream processing and assuming that the Parsortix sepa-
ration is the main point these occur (neglecting the contribution 
of the cytospin process), the HC system would have a (theoret-
ical) recovery of 118% (excess of 100% probably reflecting the 
neglected losses during cytospin that cannot easily be deconvo-
luted). This estimation shows that the HC system has a virtu-
ally full recovery of cells obtained in the upstream process.
Sample purity represents a crucial factor of CTC isolation 
techniques. However, it is most relevant when no further dis-
crimination between target cells (CTCs) and cellular back-
ground (e.g., leucocytes) takes place and when samples are 
furthermore subjected to bulk analysis. In our case, potential 
target cells on the chip are fluorescently stained using estab-
lished CTC markers as well as leucocyte exclusion markers 
allowing apt differentiation between both cellular populations. 
The microarray features themselves provide a strong reference 
to distinguish targets and unspecific background by co-locali-
zation of targets with the array features (Figure S1, Supporting 
Information). Furthermore, analysis of CTCs identified on the 
chip is based on single cell isolation and not bulk analysis, 
therefore circumventing the need for even higher purity in 
samples. Overall, leukocyte background remained under 500 
nucleated cells for all blood samples tested (data not shown). 
Sample pre-enrichment via Parsortix was shown to result in 
a residual count of 200–800 nucleated cells per mL of pro-
cessed blood,[38] translating to 1500–6000 nucleated cells post 
size-based enrichment of a standard 7.5 mL EDTA blood tube. 
This leukocyte background is known to be donor dependent.[39] 
Considering these numbers, our chip achieves a minimal fur-
ther sample purification of threefold and maximum additional 
sample purification of over 12-fold.
2.3. Cell Viability following Tumor Cell Capture
Although progress has been made during recent years, cul-
turing CTCs from patient blood ex vivo remains challenging 
to this day. So far only very few CTC-derived cell lines could 
successfully be established,[42–44] limiting the functional under-
standing of these cells. The viability of captured tumor cells fol-
lowing enrichment or isolation represents a vital prerequisite 
for successful transient or permanent culture. A cell viability 
of 99% was demonstrated for cells separated by the Parsortix 
system in earlier studies[37,45] indicating that processing of sam-
ples using this technology has a negligible effect on cell via-
bility. For this reason, in this study, we focused on assessing the 
impact of chip processing in itself on cell viability. To test the 
viability of cells passed through our chip, we sensitized breast 
cancer cell line cells (MDA-MB-468) with biotinylated-anti-
EpCAM antibodies and captured them on the streptavidin sur-
face according to standard protocol. Subsequently, dead cells 
were stained directly within the chip using 0.4% trypan blue. 
Cells were screened and images were taken in bright field 
(Figure 5). The vast majority of MDA-MB-468 cells captured 
on the chip remained viable showing no evident trypan blue 
staining. In total, around 10% of dead and 90% of viable cells 
were detected. Combined with the possibility of removing the 
PDMS microfluidic chamber and placing the glass slide con-
taining the immobilized tumor cells directly into a petri dish 
for culture, this promising result of 90% viable tumor cells fol-
lowing enrichment with the chip, suggests good starting condi-
tions for future CTC culture.
2.4. Feasibility of the Workflow for Downstream Genomic 
Analysis of Single Tumor Cells
In order to test the compatibility of our chip workflow with 
downstream molecular single cell analysis, tumor cell line cells 
(MCF-7 and SK-MEL-28 cell line cells) were spiked into a back-
ground of peripheral blood mononuclear cells (PBMCs), cap-
tured on the chip, stained with immunofluorescent markers, 
and picked by micromanipulation for subsequent whole 
genome amplification (WGA). As negative control for the 
WGA, PBS pipetted from the same chip was used, whereas 
human reference DNA was employed as positive control. Ten 
MCF-7 and 10 SK-MEL-28 single cells were used for WGA of 
which 50% (5/10) of the genomes could be successfully ampli-
fied at highest quality (4/4 bands) for each cell line, as deter-
mined by a multiplex PCR against four different fragments of 
the human GAPDH gene (Figure S2, Supporting Information). 
An additional single SK-MEL-28 cell showed 1/4 quality con-
trol bands, indicating sufficient DNA quality for PCR or Sanger 
sequencing applications. These results demonstrate compat-
ibility of the CTC chip isolation workflow with micromanipula-
tion and WGA of cells of interest for downstream applications.
3. Conclusion
In this study, we investigated the influence of ceiling struc-
ture and target cell concentration on the capture efficiency of 
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Figure 5. Viability staining of captured cancer cell line cells. Exemplary 
image of MDA-MB-468 cells taken in bright field, following capture on 
the chip. An image containing trypan blue stained cells was chosen, while 
representing the minority, to demonstrate staining efficiency. The her-
ringbone structure of the microfluidic chamber is visible as grey waves. 
Black scale bar represents 50 µm. Viable cells indicated by yellow arrow 
and dead cells stained by trypan blue indicated by red arrow.
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our CTC capture platform based on microarrays. Trialing dif-
ferent design rules, we were able to greatly enhance the cap-
ture rate in comparison to our previous design. Compared to 
other tandem systems such as pre-enrichment by Parsortix and 
detection via staining on cytospins, our system is performing 
on a competitive level. Additionally, when the cell loss during 
pre-enrichment is factored in to enable comparison to other 
microfluidic chips described in the literature working not as 
tandem device,[32,46–49] this chip platform is estimated to have a 
near full recovery. To further allow the chip platform to unfold 
its unique potential, necessary pre-enrichment steps will need 
to be addressed and refined in future studies. Furthermore, the 
chip platform is suitable for live cell capture, as demonstrated 
by a 90% viability of captured cells. These could potentially be 
used for cell culture and further downstream genomic anal-
ysis. Microfluidic systems have been shown to outperform the 
“gold standard” CellSearch device on multiple occasions.[50–56] 
However, it is important to keep in mind, that most of these 
platforms utilize additional or alternative markers for CTC iso-
lation[50–52] or work with antibody cocktails,[53,54] thereby com-
plicating the direct comparison of both approaches. At this 
point in time, we chose EpCAM as a target for CTC capture on 
our chip in order to demonstrate the feasibility of our workflow 
using a well-established marker and to allow for future direct 
comparison to the CellSearch. While we demonstrate cap-
turing by EpCAM, it should be noted that the design allows free 
exchange of used antibody without need for other changes in 
setup or operations, thus allowing virtual free choice of target 
marker. Overall, the optimized chip platform is a very prom-
ising tool enabling future studies on CTCs and other potential 
diagnostic applications.
4. Experimental Section
Microarray Printing: The microarray was printed according to the 
procedures published previously.[20] Briefly, the polydimethylsiloxane 
(PDMS, ABCR, Karlsruhe, Germany) stamps were prepared from silicon 
master (50 µm and 100 µm pitch) which was previously fabricated by 
photolithography and chemical etching process. The PDMS stamps 
were treated with oxygen plasma (0.2 mbar, 100 W, 10 sccm O2, 2 min, 
ATTO system, Diener electronics, Germany) before inking to render 
the surface hydrophilic. The stamps were spin coated (3000 rpm, 30 s) 
for homogenous coating with the ink of biotin-4-fluorescein (Sigma-
Aldrich, Germany). The stamp was first glued with two component 
epoxy resin adhesive (UHU, Germany) to a microscopic glass slide, then 
the whole glass slide was glued to the bar of a custom made holder 
and rested for 2 min to dry. The stamp holder was then attached to the 
NLP2000 system (NanoInk Inc., USA) that offers a piezo-driven stage, 
able to perform micro-printing. As substrate, the microscopy glass 
slides (Menzel Gläser, Germany) were sonicated for 10 min each in 
chloroform, isopropanol, and deionized water. The cleaned microscopy 
slides were then immersed in a solution of 3% bovine serum albumin 
(BSA, Sigma-Aldrich, Germany) in phosphate buffered saline (PBS, 
Sigma-Aldrich, Germany) overnight. The slides were then dipped ten 
times in ultrapure water (18.2 MΩcm) to remove the extra BSA and 
subsequently dried with nitrogen. After this, the BSA-coated substrates 
were ready to use for the microarray printing. The plasma-cleaned 
PDMS stamp of area 10 × 10 mm2 was levelled[29] and contacted once 
to the substrate for printing patterns having 50 µm distance between 
ink dots. Then the stamp was moved by 10 mm and contacted again to 
obtain a large area biotin dots pattern next to the already printed area. 
This process of printing was repeated four times, resulting in a total 
area of 40 × 10 mm2. Printing was done at 50–70% relative humidity 
and dwell time of 1–10 s. The biotin-4-fluorescein micropatterns were 
then immediately immobilized by a UV lamp (365 nm, Technotray CU, 
Heraeus, Germany) for 15 min after printing (bleaching the fluorescein 
and in the process photochemically binding it to the BSA) and stored at 
room temperature until use.
Fabrication of the Staggered Herringbone Chip: The microfluidic chips 
were fabricated in a three-step process. Initially, a mold was produced, 
that exhibits the inverse of the microfluidic channel including the SHB 
structure, by photolithographically patterning two layers of a negative 
photoresist (SU-8, MicroChem, USA) on a silicon wafer. A 50 µm thick 
layer of SU-8 was spin coated, followed by a soft bake. This layer was 
exposed to form the negative of the channel without grooves. After post 
exposure bake and before developing the photoresist, a second layer 
of SU-8 was spin coated and soft baked. Depending on the design, 
the rotational speed was altered to reach the groove height. The SU-8 
was then exposed to form the negative of the herringbone-shaped 
channel ceiling. Following another post exposure bake, the pattern was 
developed. Finished master templates can be reused for replica molding 
without any noticeable degradation in performance.
In the second step, PDMS prepolymer and its curing agent (Sylgard, 
184, Dow Corning, USA) were mixed at 10:1 weight ratio, degassed, and 
casted to replicate the molding template. After curing on a hot plate 
(70 °C, 4 h), the PDMS replica was carefully released from the mold. 
Fluidic inlet and outlet ports were punched with a syringe needle.
In the third step, the SHB chip was bonded onto the microarray glass 
slide by oxygen plasma treatment to form a microfluidic flow chamber. 
An additional PDMS layer was placed onto the micropattern to protect it 
during plasma exposure. Finally, tubings (material: PEEK, outer diameter 
ø = 790 µm, inner diameter ø = 250 µm, Lab-Smith, USA) were fitted 
into the punched fluid connector holes to finish the microfluidic chip 
featuring a direct syringe interface (see Figure 1b for a photograph of a 
completed chip). The smooth channel comparison chips were produced 
by attaching a commercially available smooth channel with height 
hc = 150 µm (sticky-Slide I 0.1 Luer, ibidi, Germany) onto a microarray 
glass.
Preparation and Connection of Microfluidic Chips: The connection 
procedure for the SHB chips was performed according to the procedures 
published previously.[20] The ibidi chips (with unstructured channel) 
were prepared as follows: To provide a steady flow, a 1 mL syringe (BD 
Bioscience, USA) in a syringe pump (NE-1002X, Fisher Scientific, USA) 
was directly inserted into the inlet port of an ibidi chip and the outlet port 
was connected to a tube by a male Luer lock connector (ibidi, Germany) 
for waste collection. In order to rinse the whole chamber and to block 
unspecific protein binding at the channel walls before use, 100 µL of 
PBS with 1% w/V BSA (Sigma-Aldrich, Germany) and 1% v/v Tween20 
(Fluka Analytical, Germany) was pumped into the chip and incubated 
for 15 min. Then the entire solution in the chamber was replaced with 
200 µL of cy3 labeled streptavidin in PBS (0.5% v/v). The binding of 
streptavidin on the biotin patterns was allowed for 20 min. Finally, the 
chip was flushed with 500 µL PBS to remove excess streptavidin and 
rendered ready to use.
Standard Cell Culture: MCF-7, MDA-MB-468 breast cancer cell 
line cells, and SKMEL28 melanoma cell line cells, were cultured in 
Dulbecco’s modified Eagle’s medium (Life Technologies, Germany) 
supplemented with 10% calf bovine serum (Sigma-Aldrich, Germany), 
1% l-glutamine (Gibco—Life Technologies, USA), and 1% penicillin/
streptomycin (Gibco—Life Technologies, USA) under standard cell 
culture conditions (37 °C and 5% CO2).
Preparation of Cell Culture Cells for Chip Experiments: 1 × 105 MCF-7 
cells were sensitized with 0.5 µg mL−1 of biotinylated-anti-EpCAM 
antibody (VU-1D9, Abcam, UK) in a shaker (Eppendorf Thermomixer 
Comfort, Hamburg, Germany) revolving at 300 rpm at 37 °C for 40 min. 
The biotinylated cells were then washed with PBS to remove unbound 
antibody. 100 biotinylated MCF-7 cells were manually counted and 
mixed with ≈10 000 (based on cell concentration) untreated MCF-7 
cells as negative controls in a total volume of 300 µL of pre-warmed 
0.1% BSA in PBS buffer (37 °C). This mixture was used to test and 
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compare the recovery of different microfluidic chip designs. For manual 
spiking, 10 µL of cell culture cell suspension were applied to a petri 
dish containing 1× PBS. The petri dish was then placed under a light 
microscope and focused on in 5× or 10× magnification. Using a 10 µL 
Eppendorf pipette, single cells were manually pipetted into the pipette 
tip and transferred to the respective background cell solution.
Preparation of “Mock” Blood Samples for Chip Experiments: 7.5 mL of 
whole blood was collected from healthy donors in accordance to the 
World Medical Association Declaration of Helsinki and the guidelines for 
experimentation with human materials by the Chambers of Physicians 
of the State of Hamburg (“Hamburger Ärztekammer”). Blood was 
spiked with 100 manually counted MCF-7 cells to mimic clinical cancer 
patient samples. Manually spiked cells were handled as mentioned 
above. These “mock” blood samples were pre-enriched using the size-
based Parsortix system (ANGLE plc) before applying our microfluidic 
chip assay. The function and handling of the Parsortix system has been 
described in detail in prior publications.[37] The total amount of cells 
remaining following Parsortix enrichment was between 1500 and 6000 
dependent on donor.[38,39] Cells were harvested into a 1.5 mL reaction 
tube and centrifuged at 500× g, for 5 min to replace the PBS with pre-
warmed 0.1% BSA in PBS buffer (37 °C). The pre-enriched cells were 
then incubated with 0.5 µg mL−1 of biotinylated-anti-EpCAM antibody 
(VU-1D9, Abcam, UK) in a shaker (Eppendorf Thermomixer Comfort, 
Hamburg, Germany) revolving at 300 rpm at 37 °C for 40 min. Following 
antibody incubation, the cells were centrifuged at 500 × g, for 5 min to 
remove excess antibody and subsequently re-suspended in 200 µL of 
0.1% BSA/PBS (37 °C). The sensitized pre-enriched cell fraction was 
then pumped into different microfluidic chip designs.
Capture and Staining of Tumor Cells on the Chip: The process of 
running the microfluidic chip has been described in detail in our 
prior publication.[20] In brief, the sensitized cells were pipetted into 
a 1 mL syringe (BD Bioscience, USA) which was connected to the 
device. A syringe pump passes the cells into the chip with a steady 
flow rate of 20 µL min−1. During this time, the chips were placed on 
a hot plate (Heidolph MR Hei-Tec, Schwabach, Germany) set to 37 °C. 
After a 15 min of incubation, the captured cells were fixed with 0.5% 
paraformaldehyde for 15 min and stained with DAPI (1:1000, Sigma-
Aldrich, Germany) and a secondary fluorescently labeled antibody 
(anti-mouse Alexa488-fluorophore 1:200, Abcam) for 30 min. Finally, 
chips were flushed with PBS (500 µL, 50 µL min−1) and transferred to 
microscopy for readout.
Readout of the Chips and Analysis: The entire chip area containing the 
immobilized tumor cells was manually scanned with a 10× objective on 
an upright fluorescence microscope (Eclipse 80i, Nikon Instruments 
Europe B.V., Germany) and the number of stained tumor cells bound to 
streptavidin dots was obtained by manual counting.
Viability Assessment of Captured Tumor Cells: Viability of tumor cells 
captured by the chip was assessed by trypan blue staining. Trypan blue 
is an azo dye that is only able to enter through the cell membrane of 
dead cells, staining them in a dark blue color, while live cells remain 
unstained. The blue color was visible by standard light microscopy. 1 × 
106 MDA-MB-468 cells (without leucocyte background) were processed 
through the chip according to standard protocol in a HC-type chip. A 
temperature of 37 °C was strictly maintained for the entire duration of the 
chip run and all used fluids. Following an incubation period of 15 min, 
80 µL of 0.4% trypan blue (Sigma-Aldrich, Germany) were passed 
through the chip at a flow rate of 1.2 mL h−1. Subsequently, excess dye 
was washed out with 500 µL of PBS and the chip was analyzed by bright-
field microscopy (Axiovert 200M, Zeiss, Germany). Random areas of the 
chip were selected for imaging (Software: Axiovision 4.8.2) and to assess 
the number of dead cells in relation to viable cells.
Single Cell Manipulation and Downstream Analyses: In order to 
test the efficiency of the proposed system for downstream genomic 
analyses, the complete workflow was tested for its compatibility with 
WGA and molecular characterization of the genomic material. In brief, 
breast cancer cell line MCF-7 and melanoma cell line SK-MEL-28 cells 
were transferred into a background of 60 000 PBMCs and sensitized 
with biotinylated-anti-EpCAM antibody (VU-1D9, Abcam, UK) or the 
combination of biotinylated MCAM (REA773, Miltenyi, Germany) 
and NG2 (EP1, Miltenyi, Germany) antibodies, respectively. Next, the 
enrichment and staining of tumor cells was performed in a HC-type 
chip as described above. MCF-7 cells were stained with pan-keratin 
antibody coupled to Alexa 488 (clone AE1/AE3, eBioSciences, USA), and 
SK-MEL-28 cells were stained with anti-MCAM (clone 541-10B2, Miltenyi, 
Germany) and anti-NG2 (LMH2, Novus Biological, USA) antibodies 
both coupled to PhycoErythrin. In both cases DAPI nuclear staining 
was performed. The chips were opened by removing the microfluidic 
chamber from the printed slide by cutting the PDMS layer with a scalpel. 
Single tumor cells (n = 10 for each cell line) were isolated from the 
pattern by micromanipulation, individually transferred into 0.2 mL PCR 
tubes and immediately frozen at −80 °C. Next, WGA was performed 
using the Ampli1 WGA kit (Menarini Silicon Biosystems, Italy) according 
to the manufacturer’s recommendations. The quality of the amplified 
DNA was assessed by multiplex PCR producing 96, 108–166, 299, and 
614 bp fragments from target sites in the GAPDH gene using the Ampli1 
QC Kit (Menarini Silicon Biosystems, Italy). PCR products were analyzed 
in a 1.2% agarose TAE ethidium bromide stained gel.
Statistical Analysis: Statistical analyses were performed in R.[57] ANOVA 
followed by Tukey’s pairwise analyses were employed to test the capture 
efficiency of the different ceiling type structures and patterns under the 
two different cell concentration conditions, as well as to test the recovery 
of spiking experiments using the different SHB structures. p-values of 
≤ 0.005 were considered statistically significant as recommended by 
novel statistical guidelines.[58]
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